ARTICLE | Clinical News
Isentress raltegravir: Phase III discontinued
December 6, 2010 8:00 AM UTC
Merck discontinued the double-blind, international Phase III QDMRK trial in 770 evaluable treatment-naïve patients after preliminary data showed that once-daily 800 mg Isentress missed the primary end...